Nivolumab adjuvant therapy for renal cell carcinoma

Nivolumab is in clinical development as adjuvant therapy for adult patients with localised renal cell carcinoma (RCC) who underwent surgical removal of partial or entire of a kidney. RCC (the most common type of kidney cancer in adults) is a disease that affects the lining of tiny tubes within the kidney which filter waste from the blood, making urine. Localised RCC means the cancer is either completely inside the kidney or has grown into surrounding tissues but has not spread to another part of the body. The main treatment for localised RCC is surgery to remove part or the whole kidney. After surgery, the disease may relapse and spread to other parts of the body. The aim of adjuvant treatment for localised RCC is to reduce the number of people whose disease relapse after surgery, and this remains an unmet need.